Mirae Asset Global Investments Co., Ltd. Recursion Pharmaceuticals, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 12,721 shares of RXRX stock, worth $133,952. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,721

Previous 87,539 85.47%

Holding current value

$133,952

Previous $576,000 85.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$5.7 - $8.27 $426,462 - $618,744	-74,818 Reduced 85.47%	12,721 $85,000
Q3 2024 Oct 23, 2024	BUY	$5.92 - $8.6 $477,530 - $693,710	80,664 Added 1173.29%	87,539 $576,000
Q2 2024 Jul 30, 2024	SELL	$7.35 - $10.05 $666,417 - $911,223	-90,669 Reduced 92.95%	6,875 $51,000
Q1 2024 May 01, 2024	SELL	$9.13 - $15.52 $74,208 - $126,146	-8,128 Reduced 7.69%	97,544 $972,000
Q4 2023 Jan 24, 2024	SELL	$5.09 - $10.79 $3,471 - $7,358	-682 Reduced 0.64%	105,672 $1.04 Million
Q3 2023 Oct 26, 2023	BUY	$6.59 - $15.86 $165,923 - $399,323	25,178 Added 31.02%	106,354 $813,000
Q2 2023 Aug 10, 2023	SELL	$4.56 - $9.94 $16,794 - $36,609	-3,683 Reduced 4.34%	81,176 $606,000
Q1 2023 May 04, 2023	BUY	$6.42 - $9.64 $91,285 - $137,071	14,219 Added 20.13%	84,859 $566,000
Q4 2022 Feb 09, 2023	BUY	$7.16 - $12.7 $3,408 - $6,045	476 Added 0.68%	70,640 $544,000
Q3 2022 Nov 10, 2022	BUY	$7.83 - $13.6 $259,650 - $450,989	33,161 Added 89.62%	70,164 $747,000
Q2 2022 Jul 26, 2022	BUY	$5.04 - $9.26 $186,495 - $342,647	37,003 New	37,003 $301,000

Others Institutions Holding RXRX

# of Institutions

331

Shares Held

276M

Call Options Held

2.53M

Put Options Held

2.68M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.9B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Recursion Pharmaceuticals, Inc. Transaction History